Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NVIDIA

Nvidia invested $50 million to speed up training of biotech firm Recursion's artificial intelligence models for drug discovery, which the chip designer can then potentially license out, the companies said on Wednesday.

Nvidia invests $50 mln in Recursion to train AI models for drug discovery

Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

AbCellera Biologics

Veracyte

AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been an asset to biological research and drug discovery.

Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom

Denali Therapeutics

Geron

Longevity efforts are forefront of the news cycle today, due in large part to recent coverage of tech billionaire Bryan Johnson's unique strategy to delay aging. This has investors trying to sniff out which biotech stocks to buy.

Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now

TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today celebrated the opening of its 28,000 square foot Toronto site, which will serve as the headquarters for Recursion Canada. The new site represents Recursion's significant growth in Canada and its continued investment in the local economy. In total, Recursion currently employs approximately 100 highly skilled employees in Canada, and the Toronto site is Recursion's largest site outside of its global headquarters in Salt Lake City, Utah.

Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem

Recursion's (RXRX) shares rise as it completes patient enrollment for a mid-stage study of REC-994 to treat cerebral cavernous malformations.

Recursion (RXRX) Up on Completing REC-994 Study Enrollment

Recursion Pharmaceuticals presents a compelling investment opportunity due to its AI-driven drug discovery platform, solid financials, and diverse pipeline, setting it apart from competitors like AstraZeneca, Novartis, Roche, and Biogen. The company's Q1 2023 revenue saw a 128% increase YoY, and it recently acquired AI-powered drug discovery leaders Cyclica and Valence to enhance its technological capabilities and establish an unparalleled drug discovery solution. Despite potential challenges and risks associated with their drug mechanisms, Recursion's AI-driven approach and targeted pipeline offer unique advantages over competitors, positioning it as a strong contender in the biotechnology sector.

Recursion Pharmaceuticals: Unlocking The Future Of Biotech With AI-Powered Drug Discovery

Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5. Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5.

Recursion's Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled

Recursion Pharmaceuticals just acquired a pair of AI-related biotechs. This could bolster its drug discovery capabilities and better help its clients.

Recursion Pharmaceuticals Is Going Big on AI. Here's Why It Could Be Worth Buying

Altitude's new facility will be housed within Recursion's expanded headquarters and will promote increased collaboration in Downtown Salt Lake City's rapidly growing biotech innovation ecosystem. Altitude's new facility will be housed within Recursion's expanded headquarters and will promote increased collaboration in Downtown Salt Lake City's rapidly growing biotech innovation ecosystem.

Altitude Lab Relocates to Gateway's BioHive Hub

SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer. Dr. Mauro will lead Recursion's pipeline into and through clinical development, including its five programs currently in the clinic, beginning June 1.

Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago.

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates

SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its first quarter ending March 31, 2023.

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence .

Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities

Highlights include the company's significant progress in 2022 to create a more sustainable R&D model and advance potential new medicines to patients Highlights include the company's significant progress in 2022 to create a more sustainable R&D model and advance potential new medicines to patients

Recursion Publishes Second Annual Environmental, Social and Governance Report

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -106.67% and 79.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Misses Revenue Estimates

SALT LAKE CITY, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2022.

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Salt Lake City, Utah, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rare Disease advocacy organizations and biotech and healthcare industry leaders will partner to accelerate the diagnosis and improve the care of more than 344,000 Utahns living with a rare disease. On Rare Disease Day, Feb. 28, 2023, community leaders will host a free event from 5 to 7 p.m. at Recursion Headquarters, 41 South Rio Grande Street in Salt Lake City to provide support and resources for those living or impacted by a rare disease. Additionally, Gov. Spencer J. Cox will declare February 28, 2023 Rare Disease Day in the State of Utah.

Community Leaders Unite to Provide Support and Resources for Thousands of Utahns with Rare Diseases

After losing some value lately, a hammer chart pattern has been formed for Recursion Pharmaceuticals (RXRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Bears are Losing Control Over Recursion Pharmaceuticals (RXRX), Here's Why It's a 'Buy' Now

For the first time ever, a demonstration version of one of Recursion's Compound Intelligence tools to explore maps of biology and chemistry is open for anyone to use RxRx3, the underlying dataset released alongside MolRec™, spans almost the entire human genome and is 76 times larger than all previous datasets released by Recursion combined, yet it represents less than 1% of Recursion's total data universe SALT LAKE CITY , Jan. 26, 2023 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced the public release of MolRec™ - one of its many interactive internal tools to explore the company's proprietary maps of biology and chemistry. Just as a regular map is a navigation tool in the physical world, Recursion's maps are designed to help scientists understand the topology and connectedness of human biology and chemistry to navigate the path to new medicines more efficiently.

Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day

Recursion Pharmaceuticals (RXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Recursion Pharmaceuticals (RXRX) Upgraded to Buy: What Does It Mean for the Stock?

The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Recursion Pharmaceuticals (RXRX)? Wall Street Analysts Think 53.67%

Recursion Pharmaceuticals is using artificial intelligence to make the drug discovery process efficient. They have a diverse pipeline.

Recursion Pharmaceuticals: Approaching Drug Discovery Through AI

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 2.78% and 104.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates

Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP) Initiated our Phase 1 clinical trial for the potential treatment of Clostridium difficile colitis Nominated a new clinical program in AXIN1/APC mutant cancers with an initial focus on hepatocellular carcinoma and ovarian cancer, for which a Phase 2 clinical trial is being planned Raised gross proceeds of approximately $150 million in a private placement offering SALT LAKE CITY , Nov. 8, 2022 /PRNewswire/ -- Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its third quarter ending September 30, 2022. "We are excited to have initiated four clinical trials in the past three quarters," said Chris Gibson, Ph.D.

News for Recursion Pharmaceuticals Stock (RXRX)